Direct Acting Antiviral Therapy After Liver TransplantationDirect Acting Antiviral Therapy After Liver Transplantation
Which direct acting antiviral agents are most effective for patients, and do they help contribute to long-term survival? Current Opinion in Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2016 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Liver Cancer Found in Hepatitis C Patients on New AntiviralsLiver Cancer Found in Hepatitis C Patients on New Antivirals
For patients infected with chronic hepatitis C virus, there could be a downside to direct-acting antiviral therapy, which has been hailed as a cure. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 15, 2016 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
First Evidence That Hep C Drugs Curb Liver TransplantsFirst Evidence That Hep C Drugs Curb Liver Transplants
Patients are being delisted from liver transplant wait lists because of direct-acting antiviral therapy, investigators report, but there are no long-term data to predict their future, experts caution. Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - April 15, 2016 Category: Transplant Surgery Tags: Gastroenterology News Source Type: news
Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
A new study demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 15, 2016 Category: Science Source Type: news
Antiviral therapy prolongs survival in immune tolerant hepatitis B patients
(European Association for the Study of the Liver) A new study, presented today at The International Liver Congress™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2016 Category: Infectious Diseases Source Type: news
Treating patients for hepatitis C could reduce the need for liver transplants
(European Association for the Study of the Liver) A new study presented today demonstrates that patients on the liver transplant list with hepatitis C virus (HCV) and severe liver damage were more likely to be taken off the list or have their need of a liver transplant reduced as a result of direct-acting antiviral therapy. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 14, 2016 Category: Infectious Diseases Source Type: news
Suspected Flu in a High-risk Patient? Don't Delay Antiviral Therapy
The CDC is urging physicians to be more proactive in prescribing antiviral medications for severely ill or high-risk patients in whom flu is suspected or confirmed. (Source: AAFP News)
Source: AAFP News - February 5, 2016 Category: Primary Care Source Type: news
Antiviral Therapy in Chronic Hepatitis EAntiviral Therapy in Chronic Hepatitis E
Does the latest research recommend ribavirin monotherapy as an effective and relatively safe treatment for patients with chronic hepatitis E? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 11, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Sofosbuvir and Simeprevir in Liver Transplant RecipientsSofosbuvir and Simeprevir in Liver Transplant Recipients
How safe and effective is combination antiviral therapy in the treatment of recurrent hepatitis C in liver transplant patients? Liver International (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 25, 2015 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news
FDA-approved drug protects mice from Ebola
(University of Iowa Health Care) A new study suggests that gamma interferon, which is an FDA-approved drug, may have potential as an antiviral therapy to prevent Ebola infection when given either before or after exposure to the virus. The University of Iowa study, published Nov. 12 in the journal PLOS Pathogens, found that gamma interferon, given up to 24 hours after exposure, can inhibit Ebola infection in mice and completely protect the animals from death. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 18, 2015 Category: Infectious Diseases Source Type: news
Mechanisms of Non-response to Hepatitis C TherapyMechanisms of Non-response to Hepatitis C Therapy
How does cirrhosis affect the response to antiviral therapy in patients with hepatitis C? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis
(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2015 Category: Biology Source Type: news
Perinatal HBV: Timely Immunoprophylaxis Effective Perinatal HBV: Timely Immunoprophylaxis Effective
Maternal antiviral therapy may be the next step for further decreasing perinatal HBV infections. Medscape Medical News (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - April 21, 2015 Category: OBGYN Tags: Pediatrics News Source Type: news
Researchers Explore Hepatitis B Reactivation in Patients With Rheumatoid Arthritis Treated With Both DMARD and Antiviral Therapy
No abstract available (Source: Lippincott’s Bone and Joint Newsletter)
Source: Lippincott’s Bone and Joint Newsletter - March 20, 2015 Category: Orthopaedics Tags: CME Article Source Type: news
NIH-led study to assess community-based hepatitis C treatment in Washington, D.C.
(NIH/National Institute of Allergy and Infectious Diseases) Officials from NIH and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. The trial, which will involve 600 adult D.C. residents infected with HCV alone or co-infected with HCV and HIV, also will examine the long-term effects of the treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2015 Category: Global & Universal Source Type: news
